MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ndt/gfaa372

Медицинская библиотека · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022

Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.

Seethapathy Harish, Lee Meghan D, Strohbehn Ian A, Efe Orhan, Rusibamayila Nifasha, Chute Donald F, Colvin Robert B, Rosales Ivy A, Fadden Riley M, Reynolds Kerry L, Sullivan Ryan J, Kaufman Howard L, Jhaveri Kenar D, Sise Meghan E

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Our objective was to characterize the incidence, risk factors and clinical features of acute kidney injury (AKI) in patients receiving dabrafenib and trametinib.

METHODS

We performed a retrospective cohort study examining the kidney outcomes of patients in a large healthcare system who received dabrafenib/trametinib between 2010 and 2019. The primary outcome was AKI, defined as a 1.5-fold increase in serum creatinine from baseline within a 12-month study period. AKI severity and etiology was determined for each case by chart review. Logistic regression was used to evaluate baseline predictors of AKI.

RESULTS

A total of 199 patients who received dabrafenib in our healthcare system from 2010 to 2019 were included in the analysis. Forty-two patients (21%) experienced AKI within 12 months; 10 patients (5% of the total cohort, 24% of AKI patients) experienced AKI occurring during a dabrafenib/trametinib-induced febrile syndrome characterized by fever, chills, gastrointestinal symptoms and elevated liver enzymes. Preexisting liver disease was the only significant predictor of AKI in the cohort. One patient had biopsy-proven granulomatous acute interstitial nephritis that resolved with corticosteroids.

CONCLUSIONS

Oncologists and nephrologists should be aware that AKI is common after dabrafenib/trametinib and a substantial number of cases occur in the setting of treatment-induced pyrexia.

Для цитирования: Seethapathy Harish, Lee Meghan D, Strohbehn Ian A, Efe Orhan, Rusibamayila Nifasha, Chute Donald F, Colvin Robert B, Rosales Ivy A, Fadden Riley M, Reynolds Kerry L, Sullivan Ryan J, Kaufman Howard L, Jhaveri Kenar D, Sise Meghan E. Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2022. DOI: 10.1093/ndt/gfaa372.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.